第32届ESICM:Suvratoxumab可以预防呼吸机相关性肺炎

2019-10-05 Allan MedSci原创

根据在欧洲重症监护医学学会(ESICM)第32届年会上发表的一项研究表明,Suvratoxumab可以预防重症监护病房(ICU)中的的呼吸机相关性肺炎。

根据在欧洲重症监护医学学会(ESICM)第32届年会上发表的一项研究表明,Suvratoxumab可以预防重症监护病房(ICU)中的的呼吸机相关性肺炎。这种益处在65岁以下的年轻患者中更为明显,并且与呼吸机使用时间、ICU住院时间和住院时间的缩短有关。呼吸机是一种挽救生命的干预措施,但与呼吸机相关性肺炎(VAP)的风险较高相关,金黄色葡萄球菌是最常见的原因。

呼吸机相关性肺炎(VAP)是指机械通气(MV)48小时后至拔管后48小时内出现的肺炎,是医院获得性肺炎(Hospital-acquired pneumonia,HAP)的重要类型,其中MV≤4天内发生的肺炎为早发性VAP,≥5天者为晚发性VAP。


原始出处:

http://www.firstwordpharma.com/node/1671858#axzz61Rlned4y

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2020-02-16 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2020-07-26 lfcmxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-10-07 Boyinsh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-10-07 skhzy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1912226, encodeId=6393191222696, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Feb 16 21:22:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837731, encodeId=a8f8183e731eb, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 11 07:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943620, encodeId=a3cf1943620a6, content=<a href='/topic/show?id=99e6e0152c' target=_blank style='color:#2F92EE;'>#ESICM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7015, encryptionId=99e6e0152c, topicName=ESICM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jul 26 12:22:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253271, encodeId=f51112532e1ac, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588392, encodeId=3020158839200, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Mon Oct 07 03:22:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029620, encodeId=f5fc2029620e4, content=<a href='/topic/show?id=be3d16941d3' target=_blank style='color:#2F92EE;'>#Suvratoxumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16941, encryptionId=be3d16941d3, topicName=Suvratoxumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 17 23:22:00 CST 2019, time=2019-12-17, status=1, ipAttribution=)]

相关资讯

2019 ESICM:Suvratoxumab可保护ICU患者免受金黄色葡萄球菌相关的肺炎感染

机械通气是一种挽救生命的干预措施,但伴随较高风险的呼吸机相关性肺炎(VAP),金黄色葡萄球菌感染是最常见的原因。弗朗索瓦博士说:"在几乎100%的情况下,金黄色葡萄球菌的定植先于VAP发作。"